TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today reported its financial results for the three month period ended June 30, 2016. Unless otherwise noted, all amounts are in U.S. dollars.
“Acerus continues to deliver strong revenue growth driven primarily by sales of ESTRACE®. We have also taken steps to strengthen our balance sheet and improve our overall financial picture. We look forward to the second half of the year as Aytu Bioscience begins their promotion of NATESTO™ in the U.S. and our company prepares to launch the product in Canada,” said Tom Rossi, President and Chief Executive Officer of Acerus.
“Acerus continues to deliver strong revenue growth driven primarily by sales of ESTRACE®. We have also taken steps to strengthen our balance sheet and improve our overall financial picture. We look forward to the second half of the year as Aytu Bioscience begins their promotion of NATESTO™ in the U.S. and our company prepares to launch the product in Canada,” said Tom Rossi, President and Chief Executive Officer of Acerus.
